Nov 28, 2023 9:10am EST Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
Nov 27, 2023 9:05am EST Lexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot Study
Nov 01, 2023 8:30am EDT Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
Oct 31, 2023 8:31am EDT Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
Oct 13, 2023 9:05am EDT Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
Sep 21, 2023 9:10am EDT Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
